Age and liver transplantation

Journal of Hepatology

Volumn 70, Issue 4, 2019, Pages 745-758

  Durand, François ^a,b,c   Levitsky, Josh ^d   Cauchy, François ^a   Gilgenkrantz, Hélène ^b,c   Soubrane, Olivier ^a,b   Francoz, Claire ^a,b  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Age; Deceased donor transplantation; Donation after circulatory death; Liver transplantation; Living donor liver transplantation; Waiting list mortality

Indexed keywords

AGE; AGED; AGING; CLINICAL OUTCOME; DECEASED DONOR; EPIDEMIOLOGICAL DATA; GRAFT RECIPIENT; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HUMAN; KIDNEY TRANSPLANTATION; LIVER DONOR; LIVER TRANSPLANTATION; LIVING DONOR; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW (TOPIC); ADOLESCENT; ADULT; BRAIN DEATH; CADAVER; DONOR SELECTION; FEMALE; GRAFT SURVIVAL; MALE; MIDDLE AGED; MORTALITY; PROCEDURES; RISK FACTOR; TRANSPLANTATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; BRAIN DEATH; CADAVER; DONOR SELECTION; FEMALE; GRAFT SURVIVAL; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; RISK FACTORS; TRANSPLANT RECIPIENTS; TRANSPLANTS; WAITING LISTS; YOUNG ADULT;

EID: 85061772210     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.12.009     Document Type: Review

References (141)

1. Kim, W.R., Stock, P.G., Smith, J.M., Heimbach, J.K., Skeans, M.A., Edwards, E.B., et al. OPTN/SRTR 2011 Annual Data Report: liver. Am J Transplant 13:Suppl 1 (2013), 73–102.
2. UNOS. Accessed at: https://unos.org. 2018.
3. Bilbao, I., Dopazo, C., Lazaro, J.L., Castells, L., Escartin, A., Lopez, I., et al. Our experience in liver transplantation in patients over 65 yr of age. Clin Transplant 22 (2008), 82–88.
4. Biomédecine. Adl. Accessed at: www.sipg.sante.fr. 2018.
5. Collins, B.H., Pirsch, J.D., Becker, Y.T., Hanaway, M.J., Van der Werf, W.J., D'Alessandro, A.M., et al. Long-term results of liver transplantation in older patients 60 years of age and older. Transplantation 70 (2000), 780–783.
6. Eurotransplant. Accessed at: https://eurotransplant.org. 2018.
7. Stepanova, M., Wai, H., Saab, S., Mishra, A., Venkatesan, C., Younossi, Z.M., The portrait of an adult liver transplant recipient in the United States from 1987 to 2013. JAMA Intern Med 174 (2014), 1407–1409.
8. Gane, E.J., Stedman, C.A., Hyland, R.H., Ding, X., Svarovskaia, E., Symonds, W.T., et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 368 (2013), 34–44.
9. Flemming, J.A., Kim, W.R., Brosgart, C.L., Terrault, N.A., Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology 65 (2017), 804–812.
10. Su, F., Yu, L., Berry, K., Liou, I.W., Landis, C.S., Rayhill, S.C., et al. Aging of liver transplant registrants and recipients: trends and impact on waitlist outcomes, post-transplantation outcomes, and transplant-related survival benefit. Gastroenterology 150 (2016), 441–453 e446; quiz e416.
11. Alamo, J.M., Barrera, L., Marin, L.M., Bernal, C., Suarez, G., Serrano, J., et al. Results of liver transplantation with donors older than 70 years: a case-control study. Transplant Proc 43 (2011), 2227–2229.
12. Gajate Martin, L., Martin Grande, A., Parise Roux, D., Gonzalez Cibrian, C., Fernandez Martin, C., Rodriguez Gandia, M.A., et al. Short-term results of liver transplantation with octogenarian donors. Transplant Proc 50 (2018), 184–191.
13. Nardo, B., Masetti, M., Urbani, L., Caraceni, P., Montalti, R., Filipponi, F., et al. Liver transplantation from donors aged 80 years and over: pushing the limit. Am J Transplant 4 (2004), 1139–1147.
14. Lawitz, E., Mangia, A., Wyles, D., Rodriguez-Torres, M., Hassanein, T., Gordon, S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368 (2013), 1878–1887.
15. Wong, R.J., Aguilar, M., Cheung, R., Perumpail, R.B., Harrison, S.A., Younossi, Z.M., et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148 (2015), 547–555.
16. Goldberg, D., Ditah, I.C., Saeian, K., Lalehzari, M., Aronsohn, A., Gorospe, E.C., et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology, 152, 2017 1090–1099 e1091.
17. Bhat, M., Mara, K., Dierkhising, R., Watt, K.D., Race and disease etiology predict de novo malignancy risk following liver transplantation: insights for future individualized cancer screening guidance. Transplantation, 2018.
18. Abecassis, M., Bridges, N.D., Clancy, C.J., Dew, M.A., Eldadah, B., Englesbe, M.J., et al. Solid-organ transplantation in older adults: current status and future research. Am J Transplant 12 (2012), 2608–2622.
19. Saez-Gonzalez, E., Vinaixa, C., San Juan, F., Hontangas, V., Benlloch, S., Aguilera, V., et al. Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT). Liver Int 38 (2018), 1022–1027.
20. Crespo, G., Trota, N., Londono, M.C., Mauro, E., Baliellas, C., Castells, L., et al. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. J Hepatol 69 (2018), 11–17.
21. Belli, L.S., Berenguer, M., Cortesi, P.A., Strazzabosco, M., Rockenschaub, S.R., Martini, S., et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol 65 (2016), 524–531.
22. Freeman, R.B., Edwards, E.B., Harper, A.M., Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 6 (2006), 1416–1421.
23. Cross, T.J., Antoniades, C.G., Muiesan, P., Al-Chalabi, T., Aluvihare, V., Agarwal, K., et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 13 (2007), 1382–1388.
24. Schwartz, J.J., Pappas, L., Thiesset, H.F., Vargas, G., Sorensen, J.B., Kim, R.D., et al. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience. Liver Transpl 18 (2012), 423–433.
25. Sharpton, S.R., Feng, S., Hameed, B., Yao, F., Lai, J.C., Combined effects of recipient age and model for end-stage liver disease score on liver transplantation outcomes. Transplantation 98 (2014), 557–562.
26. Garcia, C.E., Garcia, R.F., Mayer, A.D., Neuberger, J., Liver transplantation in patients over sixty years of age. Transplantation 72 (2001), 679–684.
27. Asrani, S.K., Saracino, G., O'Leary, J.G., Gonzales, S., Kim, P.T., McKenna, G.J., et al. Recipient characteristics and morbidity and mortality after liver transplantation. J Hepatol 69 (2018), 43–50.
28. Aloia, T.A., Knight, R., Gaber, A.O., Ghobrial, R.M., Goss, J.A., Analysis of liver transplant outcomes for United Network for Organ Sharing recipients 60 years old or older identifies multiple model for end-stage liver disease-independent prognostic factors. Liver Transpl 16 (2010), 950–959.
29. Sonny, A., Kelly, D., Hammel, J.P., Albeldawi, M., Zein, N., Cywinski, J.B., Predictors of poor outcome among older liver transplant recipients. Clin Transplant 29 (2015), 197–203.
30. Watt, K.D., Pedersen, R.A., Kremers, W.K., Heimbach, J.K., Sanchez, W., Gores, G.J., Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 137 (2009), 2010–2017.
31. VanWagner, L.B., Harinstein, M.E., Runo, J.R., Darling, C., Serper, M., Hall, S., et al. Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: An evaluation of the evidence and consensus recommendations. Am J Transplant 18 (2018), 30–42.
32. Prentis, J.M., Manas, D.M., Trenell, M.I., Hudson, M., Jones, D.J., Snowden, C.P., Submaximal cardiopulmonary exercise testing predicts 90-day survival after liver transplantation. Liver Transpl 18 (2012), 152–159.
33. Carey, E.J., Steidley, D.E., Aqel, B.A., Byrne, T.J., Mekeel, K.L., Rakela, J., et al. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl 16 (2010), 1373–1378.
34. Lai, J.C., Feng, S., Terrault, N.A., Lizaola, B., Hayssen, H., Covinsky, K., Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant 14 (2014), 1870–1879.
35. Wang, C.W., Covinsky, K.E., Feng, S., Hayssen, H., Segev, D.L., Lai, J.C., Functional impairment in older liver transplantation candidates: from the functional assessment in liver transplantation study. Liver Transpl 21 (2015), 1465–1470.
36. Wang, C.W., Feng, S., Covinsky, K.E., Hayssen, H., Zhou, L.Q., Yeh, B.M., et al. A comparison of muscle function, mass, and quality in liver transplant candidates: results from the functional assessment in liver transplantation study. Transplantation 100 (2016), 1692–1698.
37. Lai, J.C., Segev, D.L., McCulloch, C.E., Covinsky, K.E., Dodge, J.L., Feng, S., Physical frailty after liver transplantation. Am J Transplant 18 (2018), 1986–1994.
38. Acuna, S.A., Sutradhar, R., Kim, S.J., Baxter, N.N., Solid organ transplantation in patients with preexisting malignancies in remission: a propensity score matched Cohort study. Transplantation 102 (2018), 1156–1164.
39. Carenco, C., Faure, S., Herrero, A., Assenat, E., Duny, Y., Danan, G., et al. Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factors. Liver Int 35 (2015), 1748–1755.
40. Martin, P., DiMartini, A., Feng, S., Brown, R. Jr., Fallon, M., Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 59 (2014), 1144–1165.
41. Seree, O., Altieri, M., Guillaume, E., De Mil, R., Lobbedez, T., Robinson, P., et al. Longterm risk of solid organ de novo malignancies after liver transplantation: a French national study on 11,226 patients. Liver Transpl 24 (2018), 1425–1436.
42. Watt, K.D., Pedersen, R.A., Kremers, W.K., Heimbach, J.K., Charlton, M.R., Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 10 (2010), 1420–1427.
43. Levitsky, J., Goldberg, D., Smith, A.R., Mansfield, S.A., Gillespie, B.W., Merion, R.M., et al. Acute rejection increases risk of graft failure and death in recent liver transplant recipients. Clin Gastroenterol Hepatol, 15(584–593), 2017, e582.
44. Staatz, C.E., Tett, S.E., Pharmacokinetic considerations relating to tacrolimus dosing in the elderly. Drugs Aging 22 (2005), 541–557.
45. Benitez, C., Londono, M.C., Miquel, R., Manzia, T.M., Abraldes, J.G., Lozano, J.J., et al. Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. Hepatology 58 (2013), 1824–1835.
46. Banff Working, G., Demetris, A.J., Adeyi, O., Bellamy, C.O., Clouston, A., Charlotte, F., et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 44 (2006), 489–501.
47. Feng, S., Bucuvalas, J.C., Demetris, A.J., Burrell, B.E., Spain, K.M., Kanaparthi, S., et al. Evidence of chronic allograft injury in liver biopsy samples from long-term pediatric recipients of liver transplants. Gastroenterology, 2018.
48. Banff Working Group on Liver Allograft P, Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl 18 (2012), 1154–1170.
49. Ojo, A.O., Held, P.J., Port, F.K., Wolfe, R.A., Leichtman, A.B., Young, E.W., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349 (2003), 931–940.
50. Sharma, P., Goodrich, N.P., Zhang, M., Guidinger, M.K., Schaubel, D.E., Merion, R.M., Short-term pretransplant renal replacement therapy and renal nonrecovery after liver transplantation alone. Clin J Am Soc Nephrol 8 (2013), 1135–1142.
51. Dellon, E.S., Galanko, J.A., Medapalli, R.K., Russo, M.W., Impact of dialysis and older age on survival after liver transplantation. Am J Transplant 6 (2006), 2183–2190.
52. Leventhal, J.R., Mathew, J.M., Salomon, D.R., Kurian, S.M., Friedewald, J.J., Gallon, L., et al. Nonchimeric HLA-identical renal transplant tolerance: regulatory immunophenotypic/genomic biomarkers. Am J Transplant 16 (2016), 221–234.
53. Zhou, J., Hu, Z., Zhang, Q., Li, Z., Xiang, J., Yan, S., et al. Spectrum of De Novo cancers and predictors in liver transplantation: analysis of the scientific registry of transplant recipients database. PLoS ONE, 11, 2016.
54. Prenner, S., Levitsky, J., Comprehensive review on colorectal cancer and transplant. Am J Transplant 17 (2017), 2761–2774.
55. Kovalchik, S.A., Tammemagi, M., Berg, C.D., Caporaso, N.E., Riley, T.L., Korch, M., et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 369 (2013), 245–254.
56. National Lung Screening Trial Research T, Aberle, D.R., Adams, A.M., Berg, C.D., Black, W.C., Clapp, J.D., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (2011), 395–409.
57. National Lung Screening Trial Research T, Church, T.R., Black, W.C., Aberle, D.R., Berg, C.D., Clingan, K.L., et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med 368 (2013), 1980–1991.
58. Guichelaar, M.M., Schmoll, J., Malinchoc, M., Hay, J.E., Fractures and avascular necrosis before and after orthotopic liver transplantation: long-term follow-up and predictive factors. Hepatology 46 (2007), 1198–1207.
59. Sotaniemi, E.A., Arranto, A.J., Pelkonen, O., Pasanen, M., Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 61 (1997), 331–339.
60. Ford, E.S., Giles, W.H., Dietz, W.H., Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002), 356–359.
61. Petersen, K.F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D.L., et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300 (2003), 1140–1142.
62. Slawik, M., Vidal-Puig, A.J., Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res Rev 5 (2006), 144–164.
63. Fulop, T., Larbi, A., Kotb, R., de Angelis, F., Pawelec, G., Aging, immunity, and cancer. Discov Med 11 (2011), 537–550.
64. Timchenko, N.A., Aging and liver regeneration. Trends Endocrinol Metab 20 (2009), 171–176.
65. Zerrad-Saadi, A., Lambert-Blot, M., Mitchell, C., Bretes, H., Collin de l'Hortet, A., Baud, V., et al. GH receptor plays a major role in liver regeneration through the control of EGFR and ERK1/2 activation. Endocrinology 152 (2011), 2731–2741.
66. Wang, G.L., Salisbury, E., Shi, X., Timchenko, L., Medrano, E.E., Timchenko, N.A., HDAC1 cooperates with C/EBPalpha in the inhibition of liver proliferation in old mice. J Biol Chem 283 (2008), 26169–26178.
67. Verma, S., Tachtatzis, P., Penrhyn-Lowe, S., Scarpini, C., Jurk, D., Von Zglinicki, T., et al. Sustained telomere length in hepatocytes and cholangiocytes with increasing age in normal liver. Hepatology 56 (2012), 1510–1520.
68. Wiemann, S.U., Satyanarayana, A., Tsahuridu, M., Tillmann, H.L., Zender, L., Klempnauer, J., et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 16 (2002), 935–942.
69. Hoare, M., Das, T., Alexander, G., Ageing, telomeres, senescence, and liver injury. J Hepatol 53 (2010), 950–961.
70. Wang, M.J., Chen, F., Lau, J.T.Y., Hu, Y.P., Hepatocyte polyploidization and its association with pathophysiological processes. Cell Death Dis, 8, 2017, e2805.
71. He, S., Sharpless, N.E., Senescence in Health and Disease. Cell 169 (2017), 1000–1011.
72. Wang, M.J., Chen, F., Li, J.X., Liu, C.C., Zhang, H.B., Xia, Y., et al. Reversal of hepatocyte senescence after continuous in vivo cell proliferation. Hepatology 60 (2014), 349–361.
73. Hamilton, M.L., Van Remmen, H., Drake, J.A., Yang, H., Guo, Z.M., Kewitt, K., et al. Does oxidative damage to DNA increase with age?. Proc Natl Acad Sci U S A 98 (2001), 10469–10474.
74. Salminen, A., Ojala, J., Kaarniranta, K., Apoptosis and aging: increased resistance to apoptosis enhances the aging process. Cell Mol Life Sci 68 (2011), 1021–1031.
75. Baar, M.P., Brandt, R.M.C., Putavet, D.A., Klein, J.D.D., Derks, K.W.J., Bourgeois, B.R.M., et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell, 169, 2017 132–147 e116.
76. Zhong, H.H., Hu, S.J., Yu, B., Jiang, S.S., Zhang, J., Luo, D., et al. Apoptosis in the aging liver. Oncotarget 8 (2017), 102640–102652.
77. Ovadya, Y., Krizhanovsky, V., Strategies targeting cellular senescence. J Clin Invest 128 (2018), 1247–1254.
78. Gual, P., Gilgenkrantz, H., Lotersztajn, S., Autophagy in chronic liver diseases: the two faces of Janus. Am J Physiol Cell Physiol 312 (2017), C263–C273.
79. Mahrouf-Yorgov, M., Collin de l'Hortet, A., Cosson, C., Slama, A., Abdoun, E., Guidotti, J.E., et al. Increased susceptibility to liver fibrosis with age is correlated with an altered inflammatory response. Rejuvenation Res 14 (2011), 353–363.
80. Ilyas, G., Zhao, E., Liu, K., Lin, Y., Tesfa, L., Tanaka, K.E., et al. Macrophage autophagy limits acute toxic liver injury in mice through down regulation of interleukin-1beta. J Hepatol 64 (2016), 118–127.
81. Aravinthan, A.D., Alexander, G.J.M., Senescence in chronic liver disease: is the future in aging?. J Hepatol 65 (2016), 825–834.
82. Ruhland, M.K., Loza, A.J., Capietto, A.H., Luo, X., Knolhoff, B.L., Flanagan, K.C., et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat Commun, 7, 2016, 11762.
83. Halldorson, J.B., Bakthavatsalam, R., Fix, O., Reyes, J.D., Perkins, J.D., D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching. Am J Transplant 9 (2009), 318–326.
84. Hoofnagle, J.H., Lombardero, M., Zetterman, R.K., Lake, J., Porayko, M., Everhart, J., et al. Donor age and outcome of liver transplantation. Hepatology 24 (1996), 89–96.
85. Rana, A., Hardy, M.A., Halazun, K.J., Woodland, D.C., Ratner, L.E., Samstein, B., et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant 8 (2008), 2537–2546.
86. Dutkowski, P., Oberkofler, C.E., Slankamenac, K., Puhan, M.A., Schadde, E., Mullhaupt, B., et al. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. Ann Surg 254 (2011), 745–753 discussion 753.
87. Blok, J.J., Braat, A.E., Adam, R., Burroughs, A.K., Putter, H., Kooreman, N.G., et al. Validation of the donor risk index in orthotopic liver transplantation within the Eurotransplant region. Liver Transpl 18 (2012), 112–119.
88. Braat, A.E., Blok, J.J., Putter, H., Adam, R., Burroughs, A.K., Rahmel, A.O., et al. The Eurotransplant donor risk index in liver transplantation: ET-DRI. Am J Transplant 12 (2012), 2789–2796.
89. Feng, S., Goodrich, N.P., Bragg-Gresham, J.L., Dykstra, D.M., Punch, J.D., DebRoy, M.A., et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 6 (2006), 783–790.
90. Northup, P.G., Pruett, T.L., Kashmer, D.M., Argo, C.K., Berg, C.L., Schmitt, T.M., Donor factors predicting recipient survival after liver retransplantation: the retransplant donor risk index. Am J Transplant 7 (2007), 1984–1988.
91. Berenguer, M., Prieto, M., San Juan, F., Rayon, J.M., Martinez, F., Carrasco, D., et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36 (2002), 202–210.
92. Wali, M., Harrison, R.F., Gow, P.J., Mutimer, D., Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 51 (2002), 248–252.
93. Machicao, V.I., Bonatti, H., Krishna, M., Aqel, B.A., Lukens, F.J., Nguyen, J.H., et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 77 (2004), 84–92.
94. Condron, S.L., Heneghan, M.A., Patel, K., Dev, A., McHutchison, J.G., Muir, A.J., Effect of donor age on survival of liver transplant recipients with hepatitis C virus infection. Transplantation 80 (2005), 145–148.
95. Flores, A., Asrani, S.K., The donor risk index: a decade of experience. Liver Transpl 23 (2017), 1216–1225.
96. Kim, D.Y., Moon, J., Island, E.R., Tekin, A., Ganz, S., Levi, D., et al. Liver transplantation using elderly donors: a risk factor analysis. Clin Transplant 25 (2011), 270–276.
97. Jimenez-Romero, C., Clemares-Lama, M., Manrique-Municio, A., Garcia-Sesma, A., Calvo-Pulido, J., Moreno-Gonzalez, E., Long-term results using old liver grafts for transplantation: sexagenerian versus liver donors older than 70 years. World J Surg 37 (2013), 2211–2221.
98. Darius, T., Monbaliu, D., Jochmans, I., Meurisse, N., Desschans, B., Coosemans, W., et al. Septuagenarian and octogenarian donors provide excellent liver grafts for transplantation. Transplant Proc 44 (2012), 2861–2867.
99. Gastaca, M., Valdivieso, A., Pijoan, J., Errazti, G., Hernandez, M., Gonzalez, J., et al. Donors older than 70 years in liver transplantation. Transplant Proc 37 (2005), 3851–3854.
100. Cescon, M., Grazi, G.L., Cucchetti, A., Ravaioli, M., Ercolani, G., Vivarelli, M., et al. Improving the outcome of liver transplantation with very old donors with updated selection and management criteria. Liver Transpl 14 (2008), 672–679.
101. Ghinolfi, D., Marti, J., De Simone, P., Lai, Q., Pezzati, D., Coletti, L., et al. Use of octogenarian donors for liver transplantation: a survival analysis. Am J Transplant 14 (2014), 2062–2071.
102. Diaz Jaime, F., Berenguer, M., Pushing the donor limits: Deceased donor liver transplantation using organs from octogenarian donors. Liver Transpl 23 (2017), S22–S26.
103. Reese, P.P., Sonawane, S.B., Thomasson, A., Yeh, H., Markmann, J.F., Donor age and cold ischemia interact to produce inferior 90-day liver allograft survival. Transplantation 85 (2008), 1737–1744.
104. Gao, Q., Mulvihill, M.S., Scheuermann, U., Davis, R.P., Yerxa, J., Yerokun, B.A., et al. Improvement in Liver Transplant Outcomes From Older Donors: A US National Analysis. Ann Surg, 2018.
105. Lake, J.R., Shorr, J.S., Steffen, B.J., Chu, A.H., Gordon, R.D., Wiesner, R.H., Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 5 (2005), 549–557.
106. Gelson, W., Hoare, M., Dawwas, M.F., Vowler, S., Gibbs, P., Alexander, G., The pattern of late mortality in liver transplant recipients in the United Kingdom. Transplantation 91 (2011), 1240–1244.
107. Nasralla, D., Coussios, C.C., Mergental, H., Akhtar, M.Z., Butler, A.J., Ceresa, C.D.L., et al. A randomized trial of normothermic preservation in liver transplantation. Nature 557 (2018), 50–56.
108. Vogel, T., Brockmann, J.G., Quaglia, A., Morovat, A., Jassem, W., Heaton, N.D., et al. The 24-hour normothermic machine perfusion of discarded human liver grafts. Liver Transpl 23 (2017), 207–220.
109. Dayangac, M., Taner, C.B., Yaprak, O., Demirbas, T., Balci, D., Duran, C., et al. Utilization of elderly donors in living donor liver transplantation: when more is less?. Liver Transpl 17 (2011), 548–555.
110. Kim, S.H., Kim, Y.K., Lee, S.D., Park, S.J., Selection and outcomes of living donors with a remnant volume less than 30% after right hepatectomy. Liver Transpl 19 (2013), 872–878.
111. Ono, Y., Kawachi, S., Hayashida, T., Wakui, M., Tanabe, M., Itano, O., et al. The influence of donor age on liver regeneration and hepatic progenitor cell populations. Surgery 150 (2011), 154–161.
112. Enkhbold, C., Morine, Y., Utsunomiya, T., Imura, S., Ikemoto, T., Arakawa, Y., et al. Dysfunction of liver regeneration in aged liver after partial hepatectomy. J Gastroenterol Hepatol 30 (2015), 1217–1224.
113. Yoshizumi, T., Taketomi, A., Soejima, Y., Uchiyama, H., Ikegami, T., Harada, N., et al. Impact of donor age and recipient status on left-lobe graft for living donor adult liver transplantation. Transpl Int 21 (2008), 81–88.
114. Kubota, T., Hata, K., Sozu, T., Ueda, Y., Hirao, H., Okamura, Y., et al. Impact of donor age on recipient survival in adult-to-adult living-donor liver transplantation. Ann Surg 267 (2018), 1126–1133.
115. Goldaracena, N., Sapisochin, G., Spetzler, V., Echeverri, J., Kaths, M., Cattral, M.S., et al. Live donor liver transplantation with older (>/=50 years) versus younger (<50 years) donors: does age matter?. Ann Surg 263 (2016), 979–985.
116. Kim, S.H., Lee, E.C., Shim, J.R., Park, S.J., Right lobe living donors ages 55 years old and older in liver transplantation. Liver Transpl 23 (2017), 1305–1311.
117. Kuramitsu, K., Egawa, H., Keeffe, E.B., Kasahara, M., Ito, T., Sakamoto, S., et al. Impact of age older than 60 years in living donor liver transplantation. Transplantation 84 (2007), 166–172.
118. Shah, S.A., Cattral, M.S., McGilvray, I.D., Adcock, L.D., Gallagher, G., Smith, R., et al. Selective use of older adults in right lobe living donor liver transplantation. Am J Transplant 7 (2007), 142–150.
119. Mateo, R., Cho, Y., Singh, G., Stapfer, M., Donovan, J., Kahn, J., et al. Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant 6 (2006), 791–796.
120. Schlegel, A., Kalisvaart, M., Scalera, I., Laing, R.W., Mergental, H., Mirza, D.F., et al. The UK DCD Risk Score: a new proposal to define futility in donation-after-circulatory-death liver transplantation. J Hepatol 68 (2018), 456–464.
121. Schlegel, A., Scalera, I., Perera, M., Kalisvaart, M., Mergental, H., Mirza, D.F., et al. Impact of donor age in donation after circulatory death liver transplantation: is the cutoff “60” still of relevance?. Liver Transpl 24 (2018), 352–362.
122. Schlegel, A., Graf, R., Clavien, P.A., Dutkowski, P., Hypothermic oxygenated perfusion (HOPE) protects from biliary injury in a rodent model of DCD liver transplantation. J Hepatol 59 (2013), 984–991.
123. van Rijn, R., van Leeuwen, O.B., Matton, A.P.M., Burlage, L.C., Wiersema-Buist, J., van den Heuvel, M.C., et al. Hypothermic oxygenated machine perfusion reduces bile duct reperfusion injury after transplantation of donation after circulatory death livers. Liver Transpl 24 (2018), 655–664.
124. Darmady, E.M., Transplantation and the ageing kidney. Lancet 2 (1974), 1046–1047.
125. Frei, U., Noeldeke, J., Machold-Fabrizii, V., Arbogast, H., Margreiter, R., Fricke, L., et al. Prospective age-matching in elderly kidney transplant recipients–a 5-year analysis of the Eurotransplant Senior Program. Am J Transplant 8 (2008), 50–57.
126. Waiser, J., Schreiber, M., Budde, K., Fritsche, L., Bohler, T., Hauser, I., et al. Age-matching in renal transplantation. Nephrol Dial Transplant 15 (2000), 696–700.
127. Chapman, W.C., Vachharajani, N., Collins, K.M., Garonzik-Wang, J., Park, Y., Wellen, J.R., et al. Donor age-based analysis of liver transplantation outcomes: short- and long-term outcomes are similar regardless of donor age. J Am Coll Surg 221 (2015), 59–69.
128. Dopazo, C., Bilbao, I., Castells, L., Caralt, M., Fernandez de Sevilla, E., Lazaro, J.L., et al. Does matching donor-recipient age affect long-term survival in liver transplantation?. Ann Transplant 21 (2016), 708–716.
129. Bittermann, T., Goldberg, D.S., Quantifying the effect of transplanting older donor livers into younger recipients: the need for donor-recipient age matching. Transplantation, 2018.
130. Cucchetti, A., Ross, L.F., Thistlethwaite, J.R. Jr., Vitale, A., Ravaioli, M., Cescon, M., et al. Age and equity in liver transplantation: an organ allocation model. Liver Transpl 21 (2015), 1241–1249.
131. Schaubel, D.E., Guidinger, M.K., Biggins, S.W., Kalbfleisch, J.D., Pomfret, E.A., Sharma, P., et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant 9 (2009), 970–981.
132. Merion, R.M., Schaubel, D.E., Dykstra, D.M., Freeman, R.B., Port, F.K., Wolfe, R.A., The survival benefit of liver transplantation. Am J Transplant 5 (2005), 307–313.
133. Schaubel, D.E., Sima, C.S., Goodrich, N.P., Feng, S., Merion, R.M., The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 8 (2008), 419–425.
134. Maluf, D.G., Edwards, E.B., Kauffman, H.M., Utilization of extended donor criteria liver allograft: Is the elevated risk of failure independent of the model for end-stage liver disease score of the recipient?. Transplantation 82 (2006), 1653–1657.
135. Sebagh, M., Rifai, K., Feray, C., Yilmaz, F., Falissard, B., Roche, B., et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 37 (2003), 1293–1301.
136. Demetris, A.J., Bellamy, C., Hubscher, S.G., O'Leary, J., Randhawa, P.S., Feng, S., et al. 2016 comprehensive update of the Banff working group on liver allograft pathology: introduction of antibody-mediated rejection. Am J Transplant 16 (2016), 2816–2835.
137. Levitsky, J., Feng, S., Tolerance in clinical liver transplantation. Hum Immunol 79 (2018), 283–287.
138. Rudich, S., Busuttil, R., Similar outcomes, morbidity, and mortality for orthotopic liver transplantation between the very elderly and the young. Transplant Proc 31 (1999), 523–525.
139. Yoshizumi, T., Shirabe, K., Soejima, Y., Taketomi, A., Yamashita, N., Ikegami, T., et al. Living donor liver transplantation in patients older than 60 years. Transplantation 90 (2010), 433–437.
140. Ikegami, T., Bekki, Y., Imai, D., Yoshizumi, T., Ninomiya, M., Hayashi, H., et al. Clinical outcomes of living donor liver transplantation for patients 65 years old or older with preserved performance status. Liver Transpl 20 (2014), 408–415.
141. Ushigome H, Nakao T, Harada S, Nakamura T, Koshino K, Suzuki T, et al. Elderly living donor liver transplant recipients over 60 years old at a japanese single center. Transplant Proc.